A carregar...
Bevacizumab plus XELOX as first-line treatment of metastatic colorectal cancer: The OBELIX study
AIM: To confirm the efficacy and safety of bevacizumab/XELOX combination for the treatment of locally advanced or metastatic colorectal cancer (CRC) in Italy. METHODS: This multicentric, prospective, open-label study included patients with CRC previously untreated with chemotherapy. Patients were ad...
Na minha lista:
Publicado no: | World J Gastroenterol |
---|---|
Main Authors: | , , , , , , , , , , , , , , |
Formato: | Artigo |
Idioma: | Inglês |
Publicado em: |
Baishideng Publishing Group Inc
2015
|
Assuntos: | |
Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4476891/ https://ncbi.nlm.nih.gov/pubmed/26109816 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3748/wjg.v21.i23.7281 |
Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|